Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
J Bone Miner Res ; 26(12): 2804-11, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21786318

RESUMO

Sclerosteosis is a rare bone sclerosing dysplasia, caused by loss-of-function mutations in the SOST gene, encoding sclerostin, a negative regulator of bone formation. The purpose of this study was to determine how the lack of sclerostin affects bone turnover in patients with sclerosteosis and to assess whether sclerostin synthesis is decreased in carriers of the SOST mutation and, if so, to what extent this would affect their phenotype and bone formation. We measured sclerostin, procollagen type 1 amino-terminal propeptide (P1NP), and cross-linked C-telopeptide (CTX) in serum of 19 patients with sclerosteosis, 26 heterozygous carriers of the C69T SOST mutation, and 77 healthy controls. Chips of compact bone discarded during routine surgery were also examined from 6 patients and 4 controls. Sclerostin was undetectable in serum of patients but was measurable in all carriers (mean 15.5 pg/mL; 95% confidence interval [CI] 13.7 to 17.2 pg/mL), in whom it was significantly lower than in healthy controls (mean 40.0 pg/mL; 95% CI 36.9 to 42.7 pg/mL; p < 0.001). P1NP levels were highest in patients (mean 153.7 ng/mL; 95% CI 100.5 to 206.9 ng/mL; p = 0.01 versus carriers, p = 0.002 versus controls), but carriers also had significantly higher P1NP levels (mean 58.3 ng/mL; 95% CI 47.0 to 69.6 ng/mL) than controls (mean 37.8 ng/mL; 95% CI 34.9 to 42.0 ng/mL; p = 0.006). In patients and carriers, P1NP levels declined with age, reaching a plateau after the age of 20 years. Serum sclerostin and P1NP were negatively correlated in carriers and age- and gender-matched controls (r = 0.40, p = 0.008). Mean CTX levels were well within the normal range and did not differ between patients and disease carriers after adjusting for age (p = 0.22). Our results provide in vivo evidence of increased bone formation caused by the absence or decreased synthesis of sclerostin in humans. They also suggest that inhibition of sclerostin can be titrated because the decreased sclerostin levels in disease carriers did not lead to any of the symptoms or complications of the disease but had a positive effect on bone mass. Further studies are needed to clarify the role of sclerostin on bone resorption.


Assuntos
Proteínas Morfogenéticas Ósseas/metabolismo , Remodelação Óssea/fisiologia , Heterozigoto , Hiperostose/fisiopatologia , Modelos Biológicos , Sindactilia/fisiopatologia , Proteínas Adaptadoras de Transdução de Sinal , Adolescente , Adulto , Idoso , Biomarcadores/metabolismo , Proteínas Morfogenéticas Ósseas/sangue , Cálcio/metabolismo , Estudos de Casos e Controles , Criança , Colágeno Tipo I/sangue , Feminino , Marcadores Genéticos , Humanos , Hiperostose/sangue , Hiperostose/patologia , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/sangue , Peptídeos/sangue , Pró-Colágeno/sangue , Sindactilia/sangue , Sindactilia/patologia , Adulto Jovem
3.
Adv Otorhinolaryngol ; 65: 61-67, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17245025

RESUMO

The middle ear changes in Sclerosteosis and Van Buchem disease are described. Reduced bone resorption occurs due to faulty activity of the sclerostin molecule, a product of the recently discovered SOST gene in chromosome 17. Syndactyly draws attention to scleroteosis, and a conductive hearing loss develops before age six in both conditions. Acute, repeated attacks of facial palsy, similar to Bell's palsy, are usually the first symptoms in both conditions. Total facial nerve decompression can stop the attacks of facial paralysis. The hearing loss is a problem because new bone formation continues up to age 21. Life saving craniectomy becomes necessary when increased intracranial pressure develops, and this may have to repeated. The sclerostin molecule is now of major interest to the researchers who want to develop a treatment for osteoporosis.


Assuntos
Doenças do Desenvolvimento Ósseo/patologia , Orelha Média/patologia , Osteopetrose/patologia , Otosclerose/patologia , Proteínas Adaptadoras de Transdução de Sinal , Adolescente , Adulto , Doenças do Desenvolvimento Ósseo/genética , Proteínas Morfogenéticas Ósseas/genética , Criança , Pré-Escolar , Cromossomos Humanos Par 17 , Paralisia Facial/genética , Paralisia Facial/patologia , Marcadores Genéticos/genética , Perda Auditiva Condutiva/genética , Perda Auditiva Condutiva/patologia , Humanos , Lactente , Hipertensão Intracraniana/genética , Hipertensão Intracraniana/patologia , Síndromes de Compressão Nervosa/genética , Síndromes de Compressão Nervosa/patologia , Osteopetrose/genética , Otosclerose/genética , Crânio/patologia , Osso Temporal/patologia
4.
J Clin Endocrinol Metab ; 90(12): 6392-5, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16189254

RESUMO

BACKGROUND: Sclerosteosis is an autosomal recessive sclerosing bone disorder due to deficiency of sclerostin, a protein secreted by the osteocytes that inhibits bone formation. In the present study we assessed the effect of variable expression of the genetic defect on bone mineral density (BMD) in patients and carriers of the determinant gene. METHODS: We studied 25 individuals (seven patients and 18 phenotypically normal heterozygotes). BMD was measured by dual x-ray absorptiometry at the lumbar spine, total hip, and distal forearm, and lateral radiographs of the skull were obtained. RESULTS: Individuals with sclerosteosis had markedly increased BMD at all skeletal sites (Z-score ranges: lumbar spine, +7.73 to +14.43; total hip, +7.84 to +11.51; forearm, +4.44 to +9.53). In heterozygotes, BMD was above the mean value of healthy age-matched individuals at all skeletal sites and had a wide range of normal and clearly increased values. Skull radiographs showed the typical hyperostotic changes in affected individuals and mild or no changes in heterozygotes. CONCLUSIONS: Heterozygous carriers of sclerosteosis have BMD values consistently higher than the mean of healthy subjects without any of the bone complications encountered in homozygotes. This finding suggests that the production and/or activity of sclerostin can be titrated in vivo, leading to variable increases in bone mass without any unwanted skeletal effects, a hypothesis of obvious significance for the development of new therapeutics for osteoporosis.


Assuntos
Densidade Óssea , Doenças Ósseas Metabólicas/etiologia , Doenças Ósseas Metabólicas/metabolismo , Proteínas Morfogenéticas Ósseas/deficiência , Genes Recessivos , Heterozigoto , Proteínas Adaptadoras de Transdução de Sinal , Adolescente , Adulto , Idoso , Doenças Ósseas Metabólicas/diagnóstico por imagem , Doenças Ósseas Metabólicas/genética , Criança , Pré-Escolar , Marcadores Genéticos , Humanos , Vértebras Lombares/metabolismo , Pessoa de Meia-Idade , Radiografia , Crânio/diagnóstico por imagem
5.
FASEB J ; 19(13): 1842-4, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16123173

RESUMO

Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte-derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.


Assuntos
Doenças do Desenvolvimento Ósseo/metabolismo , Proteínas Morfogenéticas Ósseas/fisiologia , Osso e Ossos/metabolismo , Marcadores Genéticos/fisiologia , Osteócitos/metabolismo , Proteínas Adaptadoras de Transdução de Sinal , Idoso , Fosfatase Alcalina/metabolismo , Anticorpos Monoclonais/química , Biópsia , Desenvolvimento Ósseo , Doenças do Desenvolvimento Ósseo/patologia , Proteínas Morfogenéticas Ósseas/química , Remodelação Óssea , Reabsorção Óssea , Diferenciação Celular , Corantes/farmacologia , Feminino , Humanos , Processamento de Imagem Assistida por Computador , Imuno-Histoquímica , Masculino , Microscopia de Fluorescência , Pessoa de Meia-Idade , Modelos Biológicos , Osteoblastos/citologia , Osteócitos/citologia , Osteogênese , RNA Mensageiro/metabolismo , Transdução de Sinais , Fatores de Tempo , Cloreto de Tolônio/farmacologia
6.
Curr Opin Otolaryngol Head Neck Surg ; 12(5): 393-7, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15377950

RESUMO

PURPOSE OF REVIEW: Sclerosing bone dysplasias are rare genetic disorders of bone remodeling in which excessive bone formation takes place, resulting in encroachment on neural structures. The infant usually appears normal at birth, and the first sign of a problem only comes when a neurologic deficit develops, usually in the form of an acute facial palsy. Although less than 300 cases have been published, these conditions should always be considered in the differential diagnosis of facial nerve palsy, especially in children. RECENT FINDINGS: This review highlights the neurologic presentation and assessment as well as the management of sclerosing bone dysplasias. An exciting development is the recent discovery of the sclerosteosis (SOST) gene, which is involved with excessive bone formation in sclerosteosis and Van Buchem disease. Researchers in bone metabolism and pharmaceutical companies are now utilizing this knowledge to develop a medicine for osteoporosis. SUMMARY: In children and young adults an acute facial palsy, especially if it is recurrent, as well as a conductive hearing loss may be the first sign of a sclerosing bone dysplasia.


Assuntos
Perda Auditiva Condutiva/diagnóstico , Doenças do Sistema Nervoso/diagnóstico , Osteosclerose/diagnóstico , Osteosclerose/terapia , Biópsia por Agulha , Proteínas Morfogenéticas Ósseas/metabolismo , Criança , Pré-Escolar , Seguimentos , Perda Auditiva Condutiva/etiologia , Perda Auditiva Condutiva/terapia , Humanos , Imuno-Histoquímica , Masculino , Doenças do Sistema Nervoso/terapia , Exame Neurológico , Osteocondrodisplasias/diagnóstico , Osteocondrodisplasias/terapia , Otolaringologia/métodos , Medição de Risco , Índice de Gravidade de Doença
7.
J Exp Med ; 199(6): 805-14, 2004 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-15024046

RESUMO

Sclerosteosis, a skeletal disorder characterized by high bone mass due to increased osteoblast activity, is caused by loss of the SOST gene product, sclerostin. The localization in bone and the mechanism of action of sclerostin are not yet known, but it has been hypothesized that it may act as a bone morphogenetic protein (BMP) antagonist. We show here that SOST/sclerostin is expressed exclusively by osteocytes in mouse and human bone and inhibits the differentiation and mineralization of murine preosteoblastic cells (KS483). Although sclerostin shares some of the actions of the BMP antagonist noggin, we show here that it also has actions distinctly different from it. In contrast to noggin, sclerostin did not inhibit basal alkaline phosphatase (ALP) activity in KS483 cells, nor did it antagonize BMP-stimulated ALP activity in mouse C2C12 cells. In addition, sclerostin had no effect on BMP-stimulated Smad phosphorylation and direct transcriptional activation of MSX-2 and BMP response element reporter constructs in KS483 cells. Its unique localization and action on osteoblasts suggest that sclerostin may be the previously proposed osteocyte-derived factor that is transported to osteoblasts at the bone surface and inhibits bone formation.


Assuntos
Desenvolvimento Ósseo/fisiologia , Doenças do Desenvolvimento Ósseo/metabolismo , Proteínas Morfogenéticas Ósseas/metabolismo , Regulação da Expressão Gênica no Desenvolvimento , Osteoblastos/metabolismo , Proteínas Adaptadoras de Transdução de Sinal , Fosfatase Alcalina/metabolismo , Animais , Proteínas Morfogenéticas Ósseas/genética , Proteínas Morfogenéticas Ósseas/fisiologia , Células Cultivadas , Primers do DNA , DNA Complementar/genética , Proteínas de Ligação a DNA/metabolismo , Modelos Animais de Doenças , Marcadores Genéticos/genética , Marcadores Genéticos/fisiologia , Glicoproteínas , Proteínas de Homeodomínio , Humanos , Imuno-Histoquímica , Hibridização In Situ , Peptídeos e Proteínas de Sinalização Intercelular , Luciferases , Camundongos , Fosforilação , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteínas Smad , Transativadores/metabolismo , Transfecção
8.
Am J Med Genet ; 110(2): 144-52, 2002 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-12116252

RESUMO

Van Buchem disease is an autosomal recessive sclerosing bone dysplasia characterized by skeletal hyperostosis, overgrowth of the mandible, and a liability to entrapment of the seventh and eighth cranial nerves. The genetic determinant maps to chromosome 17q12-q21. We refined the critical interval to the < 1-Mb region between D17S2250 and D17S2253 in 15 affected individuals, all of whom shared a common disease haplotype. Furthermore, we report here the identification of a 52-kb deletion located within the interval and encompassing D17S1789 that is 100% concordant with the disorder. Although the deletion itself does not appear to disrupt the coding region of any known or novel gene(s), the closest flanking genes are MEOX1 on the proximal side, and SOST on the distal side of the deletion. MEOX1 is known to be important for the development of the axial skeleton, whereas the SOST gene is the determinant of sclerosteosis, a disorder that shares many features with van Buchem disease, thus raising the possibility that van Buchem disease results from dysregulation of the expression of one or both of these genes.


Assuntos
Proteínas Morfogenéticas Ósseas , Deleção Cromossômica , Cromossomos Humanos Par 17/genética , Marcadores Genéticos , Osteocondrodisplasias/genética , Proteínas Adaptadoras de Transdução de Sinal , África , Sequência de Bases , DNA Intergênico/genética , Feminino , Predisposição Genética para Doença/genética , Haplótipos , Humanos , Masculino , Repetições de Microssatélites , Países Baixos , Osteocondrodisplasias/patologia , Osteosclerose/genética , Polimorfismo de Nucleotídeo Único , Proteínas/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...